First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England

BACKGROUND4CMenB is a protein-based meningococcal B vaccine, but the vaccine antigens may be present on non-group B meningococci. In September 2015, the UK implemented 4CMenB into the national infant immunization program, alongside an emergency adolescent meningococcal ACWY (MenACWY) program to cont...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical infectious diseases 2021-10, Vol.73 (7), p.e1661-e1668
Hauptverfasser:	Ladhani, Shamez N, Campbell, Helen, Andrews, Nick, Parikh, Sydel R, White, Joanne, Edelstein, Michael, Clark, Stephen A, Lucidarme, Jay, Borrow, Ray, Ramsay, Mary E
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!